News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Deals
Iroko Pharmaceuticals Divests Antibiotic Product in Canada
May 16, 2011
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
PHILADELPHIA--(BUSINESS WIRE)--Iroko Pharmaceuticals announced today the sale of its oral antibiotic product, Vancocin® (vancomycin hydrochloride), to Merus Labs International Inc., Vancouver, Canada.
Twitter
LinkedIn
Facebook
Email
Print
Mergers & acquisitions
MORE ON THIS TOPIC
Gene editing
Pfizer Advances Beam’s Gene Editor After Pulling Hemophilia Gene Therapy
February 26, 2026
·
1 min read
·
Tristan Manalac
Weight loss
Novo Leans Into Oral Route With Weight Loss Partnership Worth up to $2.1B
February 25, 2026
·
2 min read
·
Tristan Manalac
GLP-1
Pfizer Builds Global GLP-1 Strategy With up to $495M Sciwind Deal
February 24, 2026
·
2 min read
·
Tristan Manalac
Collaboration
Astellas Bets up to $1.7B for Vir’s ‘Robust Competitor’ in Prostate Cancer
February 24, 2026
·
2 min read
·
Tristan Manalac
